Results 61 to 70 of about 10,873 (203)

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis

BMC Cardiovascular Disorders
Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF).
Ahmed Elshahat, Ahmed Mansour, Mohamed Ellabban, Ahmed Diaa, Atef Hassan, Ahmed Fawzy, Omar Abdulrahman Saad, Moaz Abouelmagd, Mahmoud Eid, Ahmed Elaraby, Mohamed Hamouda Elkasaby, Ahmed Abdelaziz   +11 more
doaj   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Integrative Approaches in Cardiovascular Disease: The Role of Nutraceuticals in Heart Failure, Atrial Fibrillation, and Related Conditions

Phytotherapy Research, EarlyView.
Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli, Ivan Corazza, Roberta Budriesi, Luca Camarda, Maria Carelli, Alberto Spadotto, Igor Diemberger   +6 more
wiley   +1 more source

Anti-inflammatory effects of eplerenone on viral myocarditis

, 2009
Inflammation contributes to increased cardiovascular morbidity and mortality associated with activation of the renin-angiotensin-aldosterone system. The aim of this study was to investigate whether eplerenone, a selective aldosterone receptor antagonist,
Xiao, Jie, Matsumori, Akira, Jie Xiao, Miho Shimada, Liu, Wenling, Dayi Hu, Hu, Dayi, Shimada, Miho, Wenling Liu, Akira Matsumori   +9 more
core   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Advanced Conduction Disease After Incident Heart Failure in Myotonic Dystrophy Type 1

Pacing and Clinical Electrophysiology, EarlyView.
Central Figure. Advanced Conduction Disease After Incident HF in Myotonic Dystrophy Type 1. ABSTRACT Background Myotonic dystrophy type 1 (DM1) is associated with progressive cardiac conduction disease, heart failure (HF) and increased mortality. However, the association of incident HF with conduction disease and survival in DM1 is not well defined ...
Isadora Guarino, Lauren Elman, Gregory Supple, Saman Nazarian   +3 more
wiley   +1 more source

Review Article: Eplerenone: An Underused Medication?

, 2010
In this article, we review the evidence supporting the use of eplerenone for improving cardiovascular prognosis. Activation of the renin-angiotensin-aldosterone system plays a major role in the pathogenesis of heart disease, and blockage of this system ...
James H. O'Keefe, Mohammad Abuannadi
core   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3656-3665, October 2026.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

Effectiveness of Bachmann's Bundle Pacing in a Patient With Severe Heart Failure and Refractory Atrial Fibrillation

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
This case report highlights CRT‐D with Bachmann's bundle pacing (BBP) in a patient with severe heart failure and refractory atrial fibrillation. BBP preserved atrioventricular conduction without PR prolongation, maintained left ventricular–only pacing, and was associated with suppression of atrial fibrillation and improvement in left atrial contractile
Yosuke Murase, Yasuhiro Ogawa, Hajime Imai, Keita Mamiya, Katsuhiro Kawaguchi   +4 more
wiley   +1 more source

Forest plots of the effects on urinary albumin or protein excretion between the eplerenone treatment groups and the controls.

, 2022
(A) Effect on 24-h Proteinuria in articles comparing eplerenone to placebo/active control. (B) Effect on microalbuminuria in articles comparing eplerenone to placebo/active control. (C) Effect on UACR for the eplerenone versus placebo.
Xiangguo Cong (12289819), Wenlong Liang (5871260), Honglei Hu (12289813), Xiaodong Zhao (327921), Shujuan Wang (30858), Xingqian Jin (12289816)   +5 more
core   +1 more source